Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer

Audhut, Aarushi; Deschoemaeker, Sofie; Allonsius, Lize; Coosemans, An; Laoui, Damya

doi:10.3390/cancers14164037

Cited by 15 publications

(10 citation statements)

References 165 publications

(282 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, mature pDCs exert immunostimulatory function, which is characterized by the production of large amounts of type I IFNs. Whereas, in the TME, pDCs with reduced production of type I IFNs favor the development of Treg cell, exert immunosuppressive effects on CTLs and promote tumor progression ( 8 , 9 , 120 , 121 ). Several studies have indicated a role for IRF4 in development of monocytes, pDCs, and cDCs ( 122 – 124 ).…”

Section: Regulation Of Irf4 In Immunosuppressive Cells In the Tmementioning

confidence: 99%

Regulatory effects of IRF4 on immune cells in the tumor microenvironment

Liang²,

Li³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

The tumor microenvironment (TME) is implicated in tumorigenesis, chemoresistance, immunotherapy failure and tumor recurrence. Multiple immunosuppressive cells and soluble secreted cytokines together drive and accelerate TME disorders, T cell immunodeficiency and tumor growth. Thus, it is essential to comprehensively understand the TME status, immune cells involved and key transcriptional factors, and extend this knowledge to therapies that target dysfunctional T cells in the TME. Interferon regulatory factor 4 (IRF4) is a unique IRF family member that is not regulated by interferons, instead, is mainly induced upon T-cell receptor signaling, Toll-like receptors and tumor necrosis factor receptors. IRF4 is largely restricted to immune cells and plays critical roles in the differentiation and function of effector cells and immunosuppressive cells, particularly during clonal expansion and the effector function of T cells. However, in a specific biological context, it is also involved in the transcriptional process of T cell exhaustion with its binding partners. Given the multiple effects of IRF4 on immune cells, especially T cells, manipulating IRF4 may be an important therapeutic target for reversing T cell exhaustion and TME disorders, thus promoting anti-tumor immunity. This study reviews the regulatory effects of IRF4 on various immune cells in the TME, and reveals its potential mechanisms, providing a novel direction for clinical immune intervention.

show abstract

Section: Regulation Of Irf4 In Immunosuppressive Cells In the Tmementioning

confidence: 99%

Regulatory effects of IRF4 on immune cells in the tumor microenvironment

Liang²,

Li³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…At present, there are several therapies for OC, including tumor resection, chemotherapy and targeted therapy. Although there has been some progress in various new treatments, about 80-85% of patients with advanced stage still relapse [15]. Some researchers explored the clinical efficacy of DC vaccine in ovarian cancer.…”

Section: Ovarian Cancermentioning

confidence: 99%

Development of cell-based vaccines in cancer treatment

Chen¹

2023

HSET

View full text Add to dashboard Cite

Cancer, as a serious global disease, becomes a severe threat to human life. Due to the problems of environmental pollution and life habits, many people die each year from various kinds of cancer, which also includes many young and middle-aged people. Nowadays, cancer has become one of the most concerned public health problems in the world, and the efforts and attempts to actively explore new treatments for cancer have never stopped. The creation of therapeutic cancer vaccines has solid biological and preclinical rationales, however, it has been difficult to translate this treatment approach into the clinical therapies. Immunotherapy has gained widespread attention as an emerging tool for cancer treatment. Among them, cell-based vaccines have achieved ideal outcomes in multiple tumor killings. This review introduces vaccines based on induced pluripotent stem cells (iPSC) and dendritic cells (DC), summarizes the related research progress of cell vaccines in cancer treatment and discusses the limitations of cell-based vaccines.

show abstract

“…Another strategy involves utilizing autologous dendritic cells activated through exposure to tumor-associated antigens, along with enhancing the cellular response through exposure to adjuvant molecules (see Figure 2 ) [ 6 , 7 ]. Dendritic cells, serving as antigen-presenting cells, are inoculated autologously and activated, mirroring the approach seen with Sipuleucel-T, an approved therapy for metastatic prostate cancer [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Role of Biofunctionalized Nanoparticles in Digestive Cancer Vaccine Development

Zdrehus,

Delcea,

Mocan

2024

Pharmaceutics

View full text Add to dashboard Cite

Nanotechnology has provided an opportunity for unparalleled development of the treatment of various severe diseases. The unique properties of nanoparticles offer a promising strategy for enhancing antitumor immunity by enhancing immunogenicity and presentation of tumor autoantigens for cancer immunotherapy. Polymeric, liposomal, carbon or silica-based nanoparticles are among those with major immunomodulatory roles in various cancer treatments. Cancer vaccines, in particular digestive cancer vaccines, have been researched and developed on nanotechnological platforms. Due to their safety, controlled release, targeting of dendritic cells (DCs) and improved antigen uptake, as well as enhanced immunogenicity, nanoparticles have been used as carriers, as adjuvants for increased effect at the tumor level, for their immunomodulating effect, or for targeting the tumor microenvironment, thereby increasing tumor immunogenicity and reducing tumor inflammatory response. This review looks at digestive cancer vaccines developed on nanoparticle platforms and the impact nanoparticles have on the effects of these vaccines.

show abstract

Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer

Cited by 15 publications

References 165 publications

Regulatory effects of IRF4 on immune cells in the tumor microenvironment

Regulatory effects of IRF4 on immune cells in the tumor microenvironment

Development of cell-based vaccines in cancer treatment

Role of Biofunctionalized Nanoparticles in Digestive Cancer Vaccine Development

Contact Info

Product

Resources

About